Zentalis Pharmaceuticals Inc (ZNTL)
$2.96
Performance
- $2.95$3.30$2.96
0.34%
Downside
Day's Volatility :10.61%
Upside
10.3%
- $2.83$25.45$2.96
4.39%
Downside
52 Weeks Volatility :88.88%
Upside
88.37%
Returns
| Period | Zentalis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -72.13% | 5.1% | 0.0% |
6 Months | -80.07% | 4.9% | 0.0% |
1 Year | -88.18% | 16.6% | 0.0% |
3 Years | -95.69% | 13.2% | -22.3% |
Highlights
Market Capitalization | 230.4M |
Book Value | $5.38 |
Earnings Per Share (EPS) | -2.41 |
Wall Street Target Price | 9.9 |
Profit Margin | 0.0% |
Operating Margin TTM | -543.77% |
Return On Assets TTM | -24.77% |
Return On Equity TTM | -42.99% |
Revenue TTM | 40.6M |
Revenue Per Share TTM | 0.57 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -219.2M |
Diluted Eps TTM | -2.41 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.0 |
EPS Estimate Next Year | -3.57 |
EPS Estimate Current Quarter | -0.84 |
EPS Estimate Next Quarter | -0.87 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 234.46%
Technicals Summary
Sell
Neutral
Buy
Zentalis Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Zentalis Pharmaceuticals Inc | -9.76% | -80.07% | -88.18% | -95.69% | -87.24% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | NA | NA | NA | -3.0 | -0.43 | -0.25 | NA | 5.38 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | Buy | $230.4M | -87.24% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Zentalis Pharmaceuticals Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 125.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 164.9%
Institutional Holdings
Matrix Capital Management Company, LLC
19.63%FMR Inc
12.20%Eventide Asset Management, LLC
12.02%Vanguard Group Inc
7.95%BlackRock Inc
6.78%State Street Corporation
5.32%
Company Information
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Organization | Zentalis Pharmaceuticals Inc |
Employees | 124 |
CEO | Dr. Kimberly Lynn Blackwell M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.96
-8.64%
Keyarch Acquisition Corp
$2.96
-8.64%
Connexa Sports Technologies Inc
$2.96
-8.64%
Us Value Etf
$2.96
-8.64%
First Wave Biopharma Inc
$2.96
-8.64%
Global X Msci Next Emerging
$2.96
-8.64%
Fat Projects Acquisition Corp
$2.96
-8.64%
Capital Link Global Fintech
$2.96
-8.64%
Applied Uv Inc
$2.96
-8.64%